{"id":"https://openalex.org/W2765415508","doi":"https://doi.org/10.1007/s40262-017-0608-3","title":"Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer\u2019s Disease","display_name":"Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer\u2019s Disease","alternate_titles":[],"publication_year":2017,"publication_date":"2017-10-23","ids":{"openalex":"https://openalex.org/W2765415508","doi":"https://doi.org/10.1007/s40262-017-0608-3","mag":"2765415508","pmid":"https://pubmed.ncbi.nlm.nih.gov/29063518","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5814546"},"language":"en","primary_location":{"id":"doi:10.1007/s40262-017-0608-3","doi":"https://doi.org/10.1007/s40262-017-0608-3","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40262-017-0608-3","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40262-017-0608-3.pdf","source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2765415508"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s40262-017-0608-3.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005005325","display_name":"John A. Hey","orcid":"https://orcid.org/0000-0002-5104-6231","observed_orcids":["https://orcid.org/0000-0002-5104-6231"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"John A. Hey","raw_affiliation_strings":["Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA. john.hey@alzheon.com","Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA. john.hey@alzheon.com","institution_ids":[]},{"raw_affiliation_string":"Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045136242","display_name":"Yongxin Yu","orcid":"https://orcid.org/0000-0002-2491-4806","observed_orcids":["https://orcid.org/0000-0002-2491-4806"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeremy Y. Yu","raw_affiliation_strings":["Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112603010","display_name":"Mark Versavel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Versavel","raw_affiliation_strings":["Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113687686","display_name":"Susan R. Abushakra","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Susan Abushakra","raw_affiliation_strings":["Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088598237","display_name":"Petr Ko\u010di\u0161","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Petr Kocis","raw_affiliation_strings":["Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110571932","display_name":"Aidan Power","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aidan Power","raw_affiliation_strings":["Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000354271","display_name":"Paul L. Kaplan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul L. Kaplan","raw_affiliation_strings":["Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082527260","display_name":"John C. Amedio","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John Amedio","raw_affiliation_strings":["Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5078511740","display_name":"Martin Tolar","orcid":"https://orcid.org/0000-0002-3910-091X","observed_orcids":["https://orcid.org/0000-0002-3910-091X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martin Tolar","raw_affiliation_strings":["Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alzheon, Inc., 111 Speen Street, Suite 306, Framingham, MA, 01701, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5005005325"],"corresponding_institution_ids":[],"apc_list":{"value":4990,"currency":"USD","value_usd":4990},"apc_paid":{"value":4990,"currency":"USD","value_usd":4990},"fwci":3.092,"has_fulltext":true,"cited_by_count":141,"citation_normalized_percentile":{"value":0.92375125,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":98,"max":100},"biblio":{"volume":"57","issue":"3","first_page":"315","last_page":"333"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tramiprosate","display_name":"tramiprosate","score":0.984000027179718},{"id":"https://openalex.org/keywords/prodrugs","display_name":"prodrugs","score":0.9210000038146973},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9750000238418579},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.6959999799728394},{"id":"https://openalex.org/keywords/gastrointestinal-tolerability","display_name":"gastrointestinal tolerance","score":0.5960000157356262},{"id":"https://openalex.org/keywords/food-effect","display_name":"food effect","score":0.8029999732971191},{"id":"https://openalex.org/keywords/single-ascending-dose","display_name":"single ascending dose","score":0.6159999966621399},{"id":"https://openalex.org/keywords/multiple-ascending-dose","display_name":"multiple ascending dose","score":0.9879999756813049},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.4320000112056732},{"id":"https://openalex.org/keywords/elimination-half-life","display_name":"elimination half-life","score":0.546999990940094},{"id":"https://openalex.org/keywords/target-dose","display_name":"target dose","score":0.31200000643730164},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.3930000066757202},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.3269999921321869}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8887425661087036},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8407274484634399},{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.7648013830184937},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6882271766662598},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5494166016578674},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.45550939440727234},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.445800244808197},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.4205087423324585},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.39709630608558655},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33229029178619385},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.136055588722229},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D002214","descriptor_name":"Capsules","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011355","descriptor_name":"Prodrugs","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011355","descriptor_name":"Prodrugs","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011355","descriptor_name":"Prodrugs","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D013607","descriptor_name":"Tablets","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013654","descriptor_name":"Taurine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013654","descriptor_name":"Taurine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013654","descriptor_name":"Taurine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D013654","descriptor_name":"Taurine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1007/s40262-017-0608-3","doi":"https://doi.org/10.1007/s40262-017-0608-3","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40262-017-0608-3","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40262-017-0608-3.pdf","source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:4730916","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5814546","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmid:29063518","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29063518","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacokinetics","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:pubmedcentral.nih.gov:5814546","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5814546/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Pharmacokinet","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1007/s40262-017-0608-3","doi":"https://doi.org/10.1007/s40262-017-0608-3","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40262-017-0608-3","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40262-017-0608-3.pdf","source":{"id":"https://openalex.org/S69290020","display_name":"Clinical Pharmacokinetics","issn_l":"0312-5963","issn":["0312-5963","1179-1926"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacokinetics","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2765415508.pdf","grobid_xml":"https://content.openalex.org/works/W2765415508.grobid-xml"},"referenced_works_count":28,"referenced_works":["https://openalex.org/W1042352716","https://openalex.org/W1561543161","https://openalex.org/W1613370405","https://openalex.org/W1966895399","https://openalex.org/W2008301592","https://openalex.org/W2025205805","https://openalex.org/W2032061707","https://openalex.org/W2044378879","https://openalex.org/W2048780418","https://openalex.org/W2051765035","https://openalex.org/W2063236931","https://openalex.org/W2068834560","https://openalex.org/W2070880671","https://openalex.org/W2078670226","https://openalex.org/W2099390250","https://openalex.org/W2106120339","https://openalex.org/W2136873160","https://openalex.org/W2148020885","https://openalex.org/W2167864502","https://openalex.org/W2185296608","https://openalex.org/W2263938816","https://openalex.org/W2329336071","https://openalex.org/W2510806376","https://openalex.org/W2526756851","https://openalex.org/W2564454435","https://openalex.org/W2606668492","https://openalex.org/W2901927471","https://openalex.org/W4388475511"],"related_works":["https://openalex.org/W2533052742","https://openalex.org/W2766989805","https://openalex.org/W4407175171","https://openalex.org/W7126394568","https://openalex.org/W2886547751","https://openalex.org/W4399172890","https://openalex.org/W2766028168","https://openalex.org/W2533869197","https://openalex.org/W2981083993","https://openalex.org/W2163049727"],"abstract_inverted_index":{"BACKGROUND:":[0],"ALZ-801":[1,142,241,294,319,331,355,416],"is":[2,14],"an":[3,73,104,202],"orally":[4],"available,":[5],"valine-conjugated":[6],"prodrug":[7],"of":[8,35,53,63,65,95,114,240,253,270,293,301,318,343,354,366,374,415,428,431,456],"tramiprosate.":[9,411],"Tramiprosate,":[10],"the":[11,33,61,110,129,136,237,249,260,299,306,328,378,425,452],"active":[12],"agent,":[13],"a":[15,49,171,178,187,198,244,282,288,362],"small-molecule":[16],"\u03b2-amyloid":[17,45],"(A\u03b2)":[18],"anti-oligomer":[19],"and":[20,29,67,92,97,121,139,145,163,166,185,201,209,213,217,219,229,267,287,323,389,396,401,439],"aggregation":[21],"inhibitor":[22],"that":[23,55,242,257,276,423],"was":[24,194,358,421],"evaluated":[25],"extensively":[26],"in":[27,60,150,159,259,340,377,387,398,442],"preclinical":[28],"clinical":[30,413],"investigations":[31],"for":[32,141,223],"treatment":[34],"Alzheimer's":[36],"disease":[37],"(AD).":[38],"Tramiprosate":[39],"has":[40],"been":[41],"found":[42,359],"to":[43,88,134,256,275,327,360,369],"inhibit":[44],"oligomer":[46],"formation":[47,64],"by":[48],"multi-ligand":[50],"enveloping":[51],"mechanism":[52],"action":[54],"stabilizes":[56],"A\u03b242":[57],"monomers,":[58],"resulting":[59],"inhibition":[62],"oligomers":[66],"subsequent":[68],"aggregation.":[69],"Although":[70],"promising":[71],"as":[72],"AD":[74,446],"treatment,":[75],"tramiprosate":[76,115,254,261,312,344,367,376,432],"exhibited":[77],"two":[78],"limiting":[79],"deficiencies:":[80],"high":[81],"intersubject":[82,285],"pharmacokinetic":[83],"(PK)":[84],"variability":[85,120,286,325],"likely":[86],"due":[87],"extensive":[89],"gastrointestinal":[90,122,302],"metabolism,":[91],"mild-to-moderate":[93],"incidence":[94,300],"nausea":[96],"vomiting.":[98],"To":[99],"address":[100],"these,":[101],"we":[102,127,235],"developed":[103],"optimized":[105],"prodrug,":[106],"ALZ-801,":[107,384],"which":[108,272,435],"retains":[109],"favorable":[111],"efficacy":[112],"attributes":[113],"while":[116],"improving":[117],"oral":[118,278,375,394,410],"PK":[119,140,231,407],"tolerability.":[123],"In":[124,233],"this":[125],"study,":[126],"summarize":[128],"phase":[130,156,262,380,453],"I":[131,157],"bridging":[132,449],"program":[133,193],"evaluate":[135],"safety,":[137],"tolerability":[138,214,397],"after":[143,277],"single":[144,172],"multiple":[146,180],"rising":[147],"dose":[148,174,182,239,414],"administration":[149],"healthy":[151,161,399],"volunteers.":[152],"METHODS:":[153],"Randomized,":[154],"placebo-controlled,":[155],"studies":[158],"127":[160],"male":[162],"female":[164],"adult":[165],"elderly":[167,402],"volunteers":[168],"included":[169],"[1]":[170],"ascending":[173,181],"(SAD)":[175],"study;":[176,184],"[2]":[177],"14-day":[179],"(MAD)":[183],"[3]":[186],"single-dose":[188],"tablet":[189,204,316,390],"food-effect":[190],"study.":[191,264],"This":[192],"conducted":[195],"with":[196,281,295,305,404,459],"both":[197,207],"loose-filled":[199,329],"capsule":[200,388],"immediate-release":[203,315],"formulation,":[205],"under":[206,248],"fasted":[208,307],"fed":[210],"conditions.":[211],"Safety":[212],"were":[215,221,273],"assessed,":[216],"plasma":[218,246,311,321,341],"urine":[220],"collected":[222],"liquid":[224],"chromatography-mass":[225],"spectrometry":[226],"(LC-MS)":[227],"determination":[228],"non-compartmental":[230],"analysis.":[232],"addition,":[234],"defined":[236],"target":[238],"delivers":[243],"steady-state":[245,363],"area":[247],"curve":[250],"(AUC)":[251],"exposure":[252,322,342,365,427],"equivalent":[255,274,368],"studied":[258],"III":[263,381,454],"RESULTS:":[265],")":[266],"AUC":[268,364,426],"exposures":[269],"tramiprosate,":[271,279],"but":[280],"substantially":[283],"reduced":[284,298],"longer":[289],"elimination":[290],"half-life.":[291],"Administration":[292],"food":[296],"markedly":[297],"symptoms":[303],"compared":[304],"state,":[308],"without":[309,336],"affecting":[310],"exposure.":[313],"An":[314],"formulation":[317],"displayed":[320],"low":[324],"similar":[326],"capsule.":[330],"also":[332],"showed":[333,392,436],"excellent":[334,393],"dose-proportionality":[335],"accumulation":[337],"or":[338],"decrease":[339],"over":[345,409],"14":[346],"days.":[347],"Based":[348],"on":[349],"these":[350],"data,":[351],"265":[352],"mg":[353,371,418,430],"twice":[356,372,419,433],"daily":[357,373],"achieve":[361],"150":[370,429],"previous":[379],"trials.":[382],"CONCLUSIONS:":[383],"when":[385],"administered":[386],"forms,":[391],"safety":[395],"adults":[400],"volunteers,":[403],"significantly":[405],"improved":[406],"characteristics":[408],"A":[412],"(265":[417],"daily)":[420],"established":[422],"achieves":[424],"daily,":[434],"positive":[437],"cognitive":[438],"functional":[440],"improvements":[441],"apolipoprotein":[443],"E4/4":[444],"homozygous":[445],"patients.":[447],"These":[448],"data":[450],"support":[451],"development":[455],"ALZ-801in":[457],"patients":[458],"AD.":[460]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2765415508","counts_by_year":[{"year":2026,"cited_by_count":17},{"year":2025,"cited_by_count":20},{"year":2024,"cited_by_count":29},{"year":2023,"cited_by_count":17},{"year":2022,"cited_by_count":20},{"year":2021,"cited_by_count":10},{"year":2020,"cited_by_count":14},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":6}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2017-11-10T00:00:00"}
